Page 1

EX - 99.23 ea135108ex99-2_cmlifescience.htm INVESTOR PRESENTATION OF THE COMPANY ON FEBRUARY 9 , 2021 2 3 sema4 Al - driven decision making as the standard of care Investor Presentation sema4 Disclaimer This confidential presentation the " presentation is being delivered to you by CM Life Sciences , Inc. ( CMLS ) and Mount Sinai Genomics , Inc. d / b / a Semas ( Sema for use by Sema4 and CMLS in connection with their proposed business combination and the offering of the securities of CMLS in a private placement ( the Transaction Any reproduction or distribution of this presentation in whole or in part or the disclosure of its contents , without the prior consent of CMLS or Semas is prohibited . By accepting this presentation , each recipient and its directors , partners officers , employees , attorney's ) , agents and representatives recipient agrees to maintain the confidentiality of all information that is contained in this presentation and not already in the public domain and 0 to return or destroy all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies No Representations and Warranties This presentation in t on is for informational purposes only and does not purport to contain all of the information that may be required to evaluate a possible investment decision with respect to CMLS The recipient agrees and acknowledges that this presentation is not intended to CMLS and Sema4 and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors , omissions or misstatements negligent or otherwise relating thereto . The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change , and any such changes may be material CMLS and Sema4 disclaim any duty to update the information contained in this presentation Forward - Looking Statements This presentation includes " forward - looking statements within the meaning of the " safe harbor provisions of the Private Securities Litigation Reform Act of 1996 CMLS's and Semad's actual results may differ from their expectations estimates and projections and consequently , you should not rely on these forward - looking statements as predictions of future events . Words such as " expect " , " estimate " " project " budget forecast " , " anticipate " , " intend " " plan may will could " should " , believes " predicts potential " " continue " and similar expressions are intended to identify such forward - looking statements . These forward - looking statements include , without limitation , CMLSs and Semad's expectations with respect to future performance and anticipated financial impacts of the Transaction the satisfaction of closing conditions to the Transaction and the timing of the completion of the Transaction . These forward - looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results . Most of these factors are outside CMLS's and Semas's control and are difficult to predict . Factors that may cause such differences include , but are not limited to : ( 1 ) the outcome of any legal proceedings that may be instituted against CMLS or Semas following the announcement of the Transaction ; ( 2 ) the inability to complete the Transaction , including due to the inability to concurently close the business combination and the private placement of common stock or due to failure to obtain approval of the stockholders of CMLS ( 3 ) delays in obtaining adverse conditions contained in , or the inability to obtain necessary regulatory approvals or complete regular reviews required to complete the Transaction : the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction ( 5 ) the inability to recognize the anticipated benefits of the Transaction , which may be affected by , among other things competition the ability of the combined company to grow and manage growth profitably , maintain relationships with o the most of the plobal COVID - 19 pandemic and ( 10 other risks and uncertainties indicatedt from time to time described in CMS registration on Form 5-1 the proxy statement relating to the Transaction including those under " Risk Factors therein and in CMLSs other sings with the US Securities and Exchange Commission ( SEC ) CMLS and Semas caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward - looking statements , including projections , which speak only as of the date made Neither CMLS nor Semas undertakes or accepts any obligation to release publicly any updates or revisions to any forward - looking statements to reflect any change in its expectations or any change in events . conditions or circumstances on which any such statement is Industry and Market Data based In this presentation , CMLS and Sema4 rely on and refer to publicly available information a I statistics regarding market participants in the sectors in which Sema4 competes and other industry data Any comparison of Semas to the industry or to any of its competitors is based on this publicly available information and statistics and such comparisons assume the reliability of the information available to Semas Semas obtained this information and statistics from third - party sources , including reports by market research firms and company filings . While Semas believes such third - party information is reliable , there can be no assurance as to the accuracy or completeness of the indicated information . Neither Sema4 nor CMLS has independently verified the information provided by the third - party sources Trademarks This presentation may contain trademarks , service marks , trade names and copyrights of other companies which are the property of their respective owners Solely for convenience , some of the trademarks , service marks , trade names and copyrights referred to in this presentation may be listed without the TM . SMC or symbols , but CMLS and Semag will assert , to the fullest extent under applicable law , the rights of the applicable owners , if any , to these trademarks , service marks , trade names and copyrights Private Placement The securities to which this presentation relates have not been registered under the Securities Act of 1933 , as amended the ' Securities Act ) , or the securities laws of any other jurisdiction CMLS is offering securities to which this presentation relates in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws . These exemptions apply to offers and sales of securities that do not involve a public offering The securities have not been approved or recommended by any federal , state or foreign securities authorities , nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete . Any representation to the contrary is a criminal offense Financial and Other Information The financial information contained in this presentation has been taken from or prepared based on the historical financial statements of Sema4 for the periods presented . An audit of these financial statements is in process . Accordingly , such financial information and data may not be included in , may be adjusted in or may be presented differently in any proxy statement to be filed with the SEC by CMLS in connection with the Transaction . We have not yet completed our closing procedures for the three months ended December 31 , 2020 This presentation contains certain estimated preliminary financial results and key operating metrics for the year ended December 31 , 2020. This information is preliminary and subject to change . As such our actual results may differ from the estimated preliminary results presented here and will not be finalized until we complete of our year - end accounting procedures Use of Projections This presentation also contains certain financial forecasts , including projected revenue . Neither CMLS's nor Semag's independent auditors have studied , reviewed , complied or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation , and accordingly , neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation . These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results in this presentation certain of the above - mentioned projected information has been provided for purposes of providing comparisons with historical data . The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business , economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information Projections are inherently uncertain due to a number of factors outside of CMLSS or Semad's control Accordingly , there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results will not differ materially from those presented in the prospective financial information Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved Disclaimer ( continued ) sema4 Additional Information and Where to Find It / Non - Solicitation In connection with the proposed transaction , CM Life Sciences intends to file a proxy statement with the US . Securities and Exchange Commission ( SEC ) . The proxy statement will be sent to the stockholders of CM Life Sciences CM Life Sciences and Semas also will file other documents regarding the proposed transaction with the SEC . Before making any voting decision investors and security holders of CM Life Sciences are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available beca because they will contain important information about the proposed transaction . Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be fled with the SEC by CM Life Sciences and Semas through the website maintained by the SEC at one sec.Doy Participants in Solicitation CM Life Sciences and Sema4 and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from CM Life Sciences ' shareholders in connection with the proposed transaction , Information about CM Life Sciences ' directors and executive officers and their ownership of CM Life Sciences ' securities is set forth in CM Life Sciences filings with the SEC . To the extent that holdings of CM Life Sciences securities have changed since the amounts printed in CM Life Sciences Registration Statement on Form S - 1 , such changes have been or will be reflected on Statements of Change in Ownership on Form 4 fled with the SEC A list of the names of such directors and executive officers and information regarding their interests in the business combination will be contained in the proxy statement / prospectus when available . You may obtain free copies of these documents as described in the preceding paragraph No Offer or Solicitation These communications do not constitute an offer to sell or the solicitation of an offer to buy any securities , or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer , solicitation or sale would be unlawful prior to registration or qualification under the securities Laws of any such jurisdiction No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act , or an exemption therefrom Overview of CM Life Sciences sema4 Unique combination of Eli Casdin's investment platform and Keith Meister's capital markets and board expertise Casdin Capital's Deep Sector Expertise ⚫ Founded in 2012 , Casdin Capital has a proven track - record as investor - partners identifying and appreciating category - defining platforms including Illumina , Adaptive , Foundation Medicine , Flatiron Health , Invitae . Clover Health , and Gingko Bioworks Fundamental Engagement On - the - ground research , close relationships with scientists and management teams and an investment focus on the long - term have supported and fueled a variety of successful financial transactions , strategic partnerships , and establishment of co - investment / accelerator models in synthetic biology and bioproduction CASDIN CAPITAL KM Their industry connections now include hundreds of critical business builders , specialists , and innovators , which allow CM Life Sciences to push forward into new opportunities while also capturing value overlooked , or left behind Keith Meister's Corporate Engagement . Mr. Meister has served as a director of 14 public companies and helped those companies structure and execute over $ 80B in transactions including spin - offs , asset sales , mergers , acquisitions and various forms of capital market transactions . Has served as founder and CIO of Corvex Management , a leading fundamental - based public market investment firm since March 2011. Previously he served as CEO of Icahn Enterprises CM Life Sciences Capital Alignment ⚫CM Life Science was founded to take advantage of a dynamic life science sector buoyed by innovation yet fragmented , where many companies are under - resourced and under - scaled ⚫ Will provide the expertise , influence , and capital to help management and the company accelerate the execution of their vision ahead of competitors CM Life Sciences Board of Industry Leaders CM Life Sciences LONG TERM CAPITAL SECULAR GROWTH Our Vision Sean George , PhD Co - founder and CEO of Invitae Munib Islam Former Co - Chief investment officer and Partner at Third Point Nat Turner Co - founder and CEO of Flatiron Health Emily Leproust , PhD Co - founder and CEO of Twist Bioscience sema4 To be the world leader at generating , collecting and analyzing longitudinal patient health data in partnership with patients and providers to deliver comprehensive solutions to help treat patients and enable next generation drug development My lifestyle choices have made my arteries more resilient My genetics make me more susceptible to breast cancer sema4 Sema4 at a Glance History Core components of Sema4 began within Mt. Sinai in 2012 ; spun out in June 2017. Sema4 team raised Icahn School of Medicine at Mt. Sinai's ranking from 31st to 3rd in the country for medical research in Genetics and drove integration of genomics into clinical care . Focus Al - driven decision making as standard of care , ushering in holistic precision medicine solutions at scale that adapt at the rate of learning Scale -1000 employees ( > 150 at MD / PhD Level ) + 10M patient records with very high consent rates > 250K annual run rate for genetic tests via owned CLIA lab 20,000 new direct connections with patients per month People • Founder and CEO of Sema4 : Dean for Precision Medicine and Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai in NY Previously chief scientist at Rosetta Inpharmatics ; Head of Genomics , Computational Biology . Systems Biology for Merck : Founding Director Sage Bionetworks ; CSO Pacific Biosciences • -450 peer - reviewed papers in leading scientific journals • h - index - 127 ( top 0.01 % of published scientists in the world ) Revenue , Patients , Data 2020 Revenue | '20 -'23E CAGR $ 190MM + | 38 % data Total Patients | w / Longitudinal | w / clinic - genomic Clinical Data ~ 10M | ~ 5M | ~ 300K Centrellis Platform Overview ⚫Integrates proprietary data feeds including genomic insights , patient records , and public databases to create a highly differentiated information platform • Enables the development of extensive disease mapping , individualized health course trajectories , and actionable treatment protocols for the healthcare ecosystem Incorporates digital tools to enable deep engagement with patients and providers across conditions and time Investors & Advisors SECTION 32 Blackstone OAK HC / FT BlackRock DEERFIELD connecticut innovations 德 诚 资本 DECHENG CAPITAL MOORE CAPITAL MANAGEMENT , LP Healthcare decisions are binary , ignoring that every individual is unique and therefore requires unique healthcare recommendations Characterizing Disease Status Over Time in Patient Population Individual patient , tracked over time , defined as well or sick based on simple , binary biomarker Patients well sick sema4 Increasingly Vast Amounts of Healthcare Data Within and Outside of Health Systems Are Available to Be Harnessed DNA Diagnoses Germ line Somatic EMR Epigenome RNA Drugs Microbiome Labs Gut Mouth Hospital Based Environment Immune Proteomics Imaging Consumer Based Procedures Cost Information Device Acquired Mobile Apps Wearable Devices Environmental Sensors Wellness Monitoring Physician Prescribed sema4 Ushering in a new era of information - driven decision making to better guide individualized healthcare ... Naïve Disease Characterization More Advanced Disease Characterization , Highlights Disease Transition More Advanced Still , with Transitions . Resolutions . and Subtypes → Personalized Treatments S1 S2 S3 Increasing Scales of Data and Advanced Predictive Modeling From the digital universe of data to actionable insights : Augmented intelligence to enable physicians and patients to make more informed decisions BIG DATA- * While McKinsey and others estimate Big Data could save medicine and pharma up to $ 100bn annually as a result of improved efficiencies in clinical trials and research , better insights for decision - marking and new tools that will help insurers , regulators , physicians and consumers make better decisions Imperfect decision making from insurers , regulators Problem : Vast amount of data is available , but not leveraged to understand disease and wellness . Our knowledge and understanding of disease / wellness is growing exponentially , but the interpretation of patient data does not yet benefit from this rapid growth of knowledge Solution : Advanced data engineering and data sciences approaches to span this divide : SPANNING THE CHASM 11 12 & physicians Patients not maximally benefitting from the latest Current State of Knowledge PREDICTIVE MODELING -DATA ENGINEERING- science Personal DNA , EMR Pharmacy Labs . Environment and Understanding PATIENT ENGAGEMENT- Device Acquired Costs related to medical errors and healthcare related infection Huge expenditure by pharma companies to bring new drug to market $ Inefficiencies in clinical trial targeting and recruitment Bioinformatics algorithms have provided extensive maps of diseases Individualized health course trajectories are now determinable Actionable treatment implications for the healthcare ecosystem Next Generation Information and Genomic Platform to Transform the Standard of Care Integrating Multidimensional Data on Patients for Advanced Assessments Constructing Innovative Predictive Models to Drive Improved Outcomes Generate Medical Insights RNA Diagnoses Drugs Microbiome 1 Labs Procedures ----------- Generate and analyze advanced genomic data to deliver more information - driven diagnostics and screening tools Lab Designed Tests Patient's Medical Data Systems to Partner with Health restructure and curate information from medical records Combining data across an expanding population database to build individualized models of disease and wellness Engage and Treat Each Patient Optimize therapy with Genetic Counseling for each patient's individualized journey Insights and Data for Pharma Collaborators -------------- Medium Low High Physician weighs risks and matches with individualized therapies The Clinical Testing Company The Direct Patient Engagement The Clinical The Clinical Data The Al Platform Company Genomics Company Management Company Company Centrellis Yields Insights That Improve Care and Drug Discovery Machine learning - based models for enhanced genomic risk prediction from our Traversa platform e.g. Polygenic risk scoring Centrellis Integrating clinical , somatic DNA , germline DNA , transcriptomic data in cancer patients for precision oncology e.g. advanced modeling for treatment response prediction / matching Deriving population - health insights from genomic data to differentiate our industry - leading tests e.g. Integrating genome - derived ancestry information for more accurate residual risk calculations CentrellisTM Enabling engagement of complex data and insights via friendly user interfaces for physicians and patients e.g. Pregnancy journey app Reconstructing longitudinal patient journeys to transform standard of care insights e.g. More accurate prediction of pregnancy complications Unique and Actionable Insights Transform the Patient Treatment Paradigm Sample Tracking , Discrete Result Generation , and Ingestion 2 Interactive Results including genetic markers , therapies , and trials 4 5 sema4 Patients & Physicians Personalized Trial Matching Long - Term Monitoring 7 Patient Ongoing Management 6 13 1 EMR Integration Plan details sent to patient Patient Reported Data returned to Personalized therapy Integrated Database , options , track patient journeys & build cohorts Monitor Treatment Plan Compliance & Mobile Patient Toxicities Applications In partnership with Health Systems , Sema4 generates clinical and patient - level insights that can be applied to enhance care and engagement at all stages of a patient's journey sema4 14 15 Through Our Platform We Develop Long - Term Relationships with Patients and Providers sema4 menu INFORMATION - RICH GENOMIC SOLUTIONS WOMEN'S HEALTH SOLUTIONS Expanded Carrier Screening Noninvasive Prenatal Screening Patient Pregnancy Journey Women's Health delivering 206k + tests / $ 200mm * revenue on current run - rate ( growing 28 % YoY ) ⚫Broad portfolio enables data continuity across the patient journey Pre - eminent brand in carrier screening • Expanding size of Expanded Carrier Screen ( ECS ) panel and adding residual risk scoring CAPABILITIES AUGMENTED BY ... ONCOLOGY SOLUTIONS Hereditary Cancer Testing Informatics Tools Whole Exome & Transcriptome Sequencing ⚫ Launched initial tests mid - 2019 with positive market reception ( growing 240 % YoY ) ⚫ Launched hereditary cancer on Traversa platform in April 2020 Launched whole exome transcriptome in June 2020 : only NY - state approved lab POPULATION HEALTH Traversa • Leveraging Traversa to offer screening drug safety through primary care providers across cancer , cardiovascular disease and • Follow - on testing and secondary insights for qualified patients through reimbursed tests Ability to pursue follow - on reimbursed clinical testing COVID - 19 testing capabilities COVID PCR and antibody testing ⚫ Testing is supported by digital patient experience , employer service dashboard and provider portal ● In - house genetic counselling services Integration with clinical workflows Advanced analytics and Al + Health system portal Stardized Genomics Platform sema4 Our Evolution Towards Oncology , Information , and Partnership Monetization WH Direct WH HS Partners COVID - 19 Pharma Partnerships Onc HS Partners One Direct Secondary Data Insights $ 190 REVENUE BY SEGMENT 2020-2023 ( $ M ) $ 265 38 % CAGR $ 360 $ 504 Segment CAGR 2020-2023 Secondary Data Oncology Insights 164 % 257 % Pharma Partnerships 129 % Health Systems " 2021-2023 CAGR Women's Health 16 % 214 % HIGHLIGHTS Sema4 is making significant investments in R & D to further develop existing offerings in addition to creating the Traversa platform . . Pharma strategic partnerships revenue driven by large size partnerships , comprising of -18 % of revenues in 2023 Growing Oncology franchise : reflects -3 % of expected revenues in 2020 and -27 % in 2023 Women's Health reflects Sema4's financial base and continued strength in genomic testing solutions Emerging secondary data insights revenue 2020E 2021E 2022E 2023E starting in 2021 Revenue Mix Evolution is Driving Meaningful Gross Margin Expansion REVENUE MIX 14 % Direct Testing Partnerships Repeat Insights 3 % 23 % 37 % 47 % 86 % 77 % 59 % 49 % 2020E 2021E 2022E 2023E Total Revenue $ 190 $ 265 $ 360 $ 504 GROSS MARGIN 32 % 22 % 54 % 41 % 4 % 16 2020E Initial investment in One Test whole exome / genome chassis 2021E Accelerating biopharma and adoption , representing partnership larger percentage of revenue , driving up gross margin 2022E Oncology information rich testing driving gross margin accretion given higher ASPS 2023E Repeat testing allows for multiple monetization paths for single run of test ; further boosting GM Note : Direct Testing includes WH Direct . Onc Direct and COVID - 19 testing revenue . Partnerships includes WH HS Partners , Pharma Partnerships , and Onc HS Partners revenue . Repeat insights includes Secondary Data Insights revenue Competitor Benchmarking 2021E to 2023E Revenue CAGR 37.9 % 46.7 % Median : 32.1 % 32.1 % 34.7 % 24.6 % 23.1 % sema4 sema4 sema4 Nateral Invitae Exact Guardant Adaptive Sciences Health Biotechnologies 2022E Revenue $ 2.193 $ 360 $ 585 $ 700 $ 508 $ 225 sema4 Natera Invitae Exact Sciences Guardant Health Adaptive Biotechnologies 2022E Gross Margin Median : 72.1 % 76.9 % 72.1 % 72.5 % 56.4 % 52.8 % 41.0 % sema4 Nateral Invitae Exact Guardant Adaptive Sciences Health Biotechnologies Current Lead Therapeutic Area Women's Women's Women's Oncology Oncology Oncology Health Health Health semaд 17 Wall street research and Cap 10 Estimates as of 02/05/2021 10 Represents 2001E to 2002E revenue growth 18 Our Ongoing Transformation Will Drive Best - in - Class Financial Performance ACCELERATING TOPLINE GROWTH off Strong Revenue Base EXPANDING MARGIN PROFILE Driven by Improving Product Volume & Mix HEALTH SYSTEM & PHARMA PARTNERSHIPS Provide Partnership Revenue with Attractive Unit Economics CLEAR PATH TO PROFITABILITY with Strong Operating Leverage TOTAL REVENUE ( SM ) CAGR : 38 % $ 504 $ 190 Forward revenue CAGR of 38 % Growth driven by genomic solutions , secondary insights and pharma partnerships 2020 2023 GROSS MARGIN +3,161 bps 54.1 % Sema4 benefits from volume purchasing 22.5 % Decreasing cost per sample across testing verticals as Traversa platform and pharma partnerships drive margins in 2020 2023 % OF TOTAL REV . FROM PARTNERSHIPS 2020 2023 outer years Partnerships with health systems and pharma typically structured with sizeable upfront payment providing capital cushion 30 % Monthly revenues with robust margins provide strong visibility into near - term performance OPEX % OF TOTAL REV . ( 770 ) bps High proportion of fixed costs in both operating 68.6 % 60.9 % expenditures and COGS Path to meaningfully achieve operating leverage and long - term operating margin expansion 2020 2023 Accelerating Health System Partnerships Will Underpin Our Growth : Revenue , Patients , Data Data Features growing 100x 30M Patients sema4 PLAN FOR EXPANSION 1 Recruit and build health system partnerships 2 Integrating into care Sign up incremental systems leveraging value of state of the art . genomic testing solutions at no cost , increasing access to patient data Directly measuring and demonstrating clinical utility of direct impacts to health systems and measuring impact 8. Systems 3 3 Years Investments to scale population - based genomic testing Combining data across expanding population databases enable holistic models of disease and wellness , including precision oncology Utilizing data scientists , network modelling , and clinical trials to support 4 Data science health trajectory outcomes . capabilities 14M , ' Patents 4 Systems 2021 Access to Patient Data Features Data access compounds via health system partners where access is provided through third - party agreements , as well as directly from tested patients who consent to provide Sema4 with access to their records ( at a rate of -85 % ) . 19 Health Systems sema4 Centrellis platform has utility across the spectrum of disease & wellness to transform standard of care Sema4 is filling a white space to unify the engagement with stakeholders across the healthcare ecosystem and reflects a novel approach where significant investment has yet to be seen . Investments in Segment Technology Auto - Immune > $ 100B semaд Addressable Market Oncology Pregnancy $ 171B $ 2B ' Oncology investment Diabetes $ 176B Patient Life Cycle " Reflects annual cost of pregnancy complications 20 Nustrative - Not to Scale concentration Beckers - Pregnancy Complication Costs Health Payer Intelligence - Cardiovascular . Diabetes , and Oncology Annual Costs : HCP Live - Auto - Immune Annual Costs 21 Sema4 Differentiation INSIGHTS AND ENGAGEMENT Standard of Care Focus Clinical Clinical Reports Trials Enhanced Data Feed Standard Dx Pathway Consumer Focus Clinical Decision Population Health Support Models Molecular . Clinical Patient Generated Data Laboratory Centrellis ™ Insights Engine EMR , Imag Molecular , i Data Management Engine [ Channels ] Health System Centrellis Capability Key Cardiovascular Disease $ 194B sema4 Population - health insights Machine learning - based models Engagement of complex data and insights Integrating disparate data to inform precision medicine Transforming standard of care insights Patient & Pharma Research Focus Real - World Drug Discovery Provider Portals Evidence EMR , Imaging Molecular , Claims Third - Party Models Knowledge Inferences cs Omics repe Literature , Knowledge Graph repositories Outside Data Source sema4 Four Foundational Pillars Will Enable Us to Achieve Our Vision We are building a unique data ecosystem and platform containing deep data from increasing numbers of consenting patients ( currently millions ) engaged by our platform or partnered health systems 22 XX STATE - OF - THE - ART GENOMIC INFASTRUCTURE . Information - rich women's health , oncology , and population health solutions Analyzes and interprets extensive information on diseases , mutations , and frequency across population ACCESS & ENGAGEMENT Direct holistic patient engagement on an ongoing basis gives industry leading consented access Patient engagement across the care continuum driven by standard of care genomic testing solutions DEEP & STRUCTURED DATA Longitudinal clinical , molecular , and genetic patient information Originates from patients with long - term relationships and are re - contactable UNIQUE INSIGHTS Actionable and personalized . insights for patients , health system providers , payors , and pharma that inform decisions Using advanced predictive models developed on deep . structured data across continuum of care sema4 Case Study : Traversa Platform A COMPREHENSIVE EXOME / WHOLE GENOME FRAMEWORK TO ADAPT AT THE RATE OF LEARNING Platform Pharmacogenomics 88 Hereditary Carrier cancer screening 20 | 182 адо 88 Polygenic risk Carrier scores screening PGx Hereditary cancer Exhibit 99.2